### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau



## 

# (43) International Publication Date 24 December 2003 (24.12.2003)

### PCT

# (10) International Publication Number WO 03/106488 A2

(51) International Patent Classification7:

C07K 14/52

(21) International Application Number: PCT/EP03/50211

(22) International Filing Date:

3 June 2003 (03.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 02100697.8

12 June 2002 (12.06.2002) EP

- (71) Applicant (for all designated States except US): AP-PLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; Pietermaai 15, NL-NL Curaçao (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PROUDFOOT, Amanda [CH/FR]; Sous Chens, F-74140 Chens Sur Leman (FR). KOSCO-VILBOIS, Marie [US/FR]; Le Cret, F-74270 Minzier (FR).
- (74) Agent: SERONO INTERNATIONAL S.A. INTEL-LECTUAL PROPERTY; 12, Chemin des Aulx, CH-1228 Plan-les-Ouates (CH).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

•

(54) Title: NOVEL ANTAGONISTS OF CXCR3-BINDING CXC CHEMOKINES

(57) Abstract: Novel antagonists of CXCR3 -binding CXC chemokines, and in particular of human CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can be used to block the activity of CXCR3-binding CXC chemokines on CXCR3 -expressing cells, thereby providing therapeutic compositions for use in the treatment or prevention of diseases related to excessive activated T cells migration, such as graft rejection and autoimmune diseases, and of diseases needing an increase of vascularization, such as ischemic heart disease.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 24 December 2003 (24.12.2003)

PCT

# (10) International Publication Number WO 2003/106488 A3

(51) International Patent Classification<sup>7</sup>: C07K 14/52, 19/00, C12N 15/19, 15/62, A61K 38/19, C12N 5/06, 5/08

(21) International Application Number:

PCT/EP2003/050211

(22) International Filing Date: 3 June 2003 (03.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 02100697.8

12 June 2002 (12.06.2002) EF

EP SE, SI, SI GA, GN,

(71) Applicant (for all designated States except US): AP-PLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; Pietermaai 15, NL-NL Curaçao (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PROUDFOOT, Amanda [CH/FR]; Sous Chens, F-74140 Chens Sur Leman (FR). KOSCO-VILBOIS, Marie [US/FR]; Le Cret, F-74270 Minzier (FR).

(74) Agent: SERONO INTERNATIONAL S.A. INTEL-LECTUAL PROPERTY; 12, Chemin des Aulx, CH-1228 Plan-les-Ouates (CH). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 15 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTAGONISTS OF CXR3-BINDING CXC CHEMOKINES

(57) Abstract: Novel antagonists of CXCR3 -binding CXC chemokines, and in particular of human CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can be used to block the activity of CXCR3-binding CXC chemokines on CXCR3 -expressing cells, thereby providing therapeutic compositions for use in the treatment or prevention of diseases related to excessive activated T cells migration, such as graft rejection and autoimmune diseases, and of diseases needing an increase of vascularization, such as ischemic heart disease.



## INTERNATIONAL SEARCH REPORT

International lication No PCT/EP 03/50211

			101/11 03/30211					
A. CLASSIF IPC 7	CATION OF SUBJECT MATTER C07K14/52 C07K19/00 C12N15/ C12N5/06 C12N5/08	/19 C12N15/	62 A61K38/19					
According to	According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS S	SEARCHED .							
Minimum doc IPC 7	currentation searched (classification system followed by classification $C07K-C12N-A61K$	ation symbols)						
	on searched other than minimum documentation to the extent tha							
	ata base consulted during the international search (name of data BS Data, WPI Data, EPO-Internal, B							
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT							
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.					
A	US 5 739 103 A (ROLLINS ET AL.) 14 April 1998 (1998-04-14) column 2 -column 3; claims 1,3,	8						
A	US 2002/018776 A1 (HANCOCK) 14 February 2002 (2002-02-14) column 3; claims 8-10							
A	US 6 140 064 A (MOSER BERNHARD 31 October 2000 (2000-10-31) the whole document	ET AL)						
A	US 5 977 334 A (RANSOHOFF RICHARD ET AL) 2 November 1999 (1999-11-02) column 3; figure 1A							
		-/						
			1					
X Fur	ther documents are listed in the continuation of box C.	X Patent famil	y members are listed in annex.					
Special categories of cited documents:     Tater document published after the international filling date.								
"A" docum	*A* document defining the general state of the art which is not considered to be of particular relevance  or priority date and not in conflict with the application but cled to understand the principle or theory underlying the invention							
'E' earlier	"E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to							
"L" document which may throw doubts on priority claim(s) or involve an inventive step when the document is taken alone which is clied to establish the publication date of another "V" document of particular relevance; the claimed invention								
citation or other special reason (as specified)  Cannot be considered to involve an inventive step when the document referring to an oral disclosure, use, exhibition or other means the means the considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled								
*P* docum	other means  *P* document published prior to the international filing date but later than the priority date claimed  *&* document member of the same patent family							
	e actual completion of the international search		of the international search report					
1	14 January 2004 09/02/2004							
Name and	Name and mailing address of the ISA Authorized officer							
	European Patem Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk TeL (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Schmid	Schmidt, Harald					



International lication No PCT/EP 03/50211

		PCI/EF US	
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication where appropriate, of the relevant passages		Relevant to claim No.
A	WO 02 43758 A (SCHERING CORP) 6 June 2002 (2002-06-06) claims 1-8		
Α	US 5 656 724 A (DALY THOMAS J ET AL) 12 August 1997 (1997-08-12) SEQ ID NO:7; column 3 -column 4; claims 1-6; figure 1		
A	US 5 969 093 A (CARLIN MCKEOUGH ET AL) 19 October 1999 (1999-10-19) SEQ ID NO:9; column 10		
Α	WO 02 04015 A (BRADBURNE JAMES A ;BOTTI PAOLO (US); CHEN SHIAH YUN (US); CRESSMAN) 17 January 2002 (2002-01-17) SEQ ID NO:24; page 6; claims 1-7; figure 10D		
А	LOETSCHER P ET AL.: "The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 5, 2 February 2001 (2001-02-02), pages 2986-2991, XP002266874 the whole document		
		·	



### INTERNATIONAL SEARCH REPORT

Internation application No. PCT/EP 03/50211

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)				
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
	Although claims 34 to 36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.				
2. X	Claims Nos.: 1,5-11,13-36 (all partially) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:				
	see FURTHER INFORMATION sheet PCT/ISA/210				
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).				
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)				
This inte	ernational Searching Authority found multiple inventions in this international application, as follows:				
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.				
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3.	As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:				
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:				
Remar	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.				

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,5-11,13-36 (all partially)

The scope of claims 13-36, in as far as the expressions "antagonists of claims 1 to 12 wherein one or more amino acids '...! have been '...! deleted", "mimetics", "active fractions", "precursors" and "derivatives" are concerned, is so unclear (Article 6 PCT) that a meaningful International Search is impossible with regard to these expressions.

Moreover, present claims 1,5-11 and 13-36 relate to antagonists defined by reference to the sequence of human mature CXCL11.

1.) Mutants of CXCL9 are based on a substitution of at least one basic residue at positions 46,62,66 and 70 of human mature CXCL11. However, due to a gap in the sequence of CXCL9 at corresponding position 47, the numbering of the following residues of CXCL9 is unclear with regard to the basic residues to be substituted (see e.g. the two lysine residues at positions 65 and 66 of CXCL9 corresponding to positions 66 and 67 of human mature CXCL11).

2.) Mutants of human CXCL10 are additionally substituted at positions corresponding to residue numbers 74 and 75 of human mature CXCL11. However, since human mature CXCL11 has only 73 amino acid residues, this reference remains totally unclear.

The use of these references to human mature CXCL11 in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the positions the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible.

Consequently, the search has been restricted to those parts of the claims relating to antagonists consisting of and comprising mutants of (1) CXCL11, (2) CXCL10 without the additional substitutions at positions 74 and 75, and (3) CXCL9 without the substitutions at positions 66 and 70.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Pication No PCT/EP 03/50211

Patent document ited in search report		Publication date	<del> </del>	Patent family member(s)	Publication date
JS 5739103	A	14-04-1998	US	5459128 A	17-10-1995
JJ J/JJ10J	••		ĒΡ	0828833 A1	18-03-1998
			ĴΡ	11506005 T	02-06-1999
			WO.	9638559 A1	05-12-1996
			ÜS	5705360 A	06-01-1998
			ÜS	5854412 A	29-12-1998
			AT	204583 T	15-09-2001
			CA	2176217 A1	18-05-1995
			DE	69428049 D1	27-09-2001
			DE	69428049 T2	18-04-2002
			DK	725794 T3	10-12-2001
			EP	0725794 A1	14-08-1996
			ES	2162908 T3	16-01-2002
			JP	9505053 T	20-05-1997
			PT	725794 T	28-02-2002
			พ่ง	9513295 A1	18-05-1995
US 2002018776	A1	14-02-2002	AU	5349601 A	30-10-2001
·			WO	0178708 A1	25-10-2001 
US 6140064	Α	31-10-2000	AU	734090 B2	07-06-2001
			AU	4260897 A	02-04-1998
			CA	2265915 A1	19-03-1998
			EΡ	0925358 A1	30-06-1999
			JP	2002513388 T	08-05-2002
			WO	9811218 A1	19-03-1998
			US	2003158392 A1	21-08-2003
			US	6184358 B1	06-02-2001
US 5977334	. A	02-11-1999	US	6414118 B1	02-07-2002
WO 0243758	 A	06-06-2002	AU	2575602 A	11-06-2002
			CA	2430401 A1	06-06-2002
			WO	0243758 A2	06-06-2002
			US 	2002111290 A1	15-08-2002 
US 5656724	Α	12-08-1997	AU	4013495 A	23-05-1996
			CA	2202889 A1	09-05-1996
			EP	0786001 A1	30-07-1997
			WO	9613587 A1	09-05-1996
			US	5789539 A	04-08-1998
US 5969093	Α	19-10-1999	US	5707829 A	13-01-1998
			US	2002193567 A1	19-12-2002
			AU	727480 B2	14-12-2000
			AU	6712396 A	18-02-1997
			AU	727489 B2	14-12-2000
			AU	6768596 A	12-03-1997
			CA	2227220 A1	06-02-1997
			CA	2229208 A1	27-02-1997
			EP	0839196 A2	06-05-1998
				ハントエクフト ハク	08-07-1998
			EP	0851875 A2	
			JP	11510045 T	07-09-1999
			JP JP	11510045 T 2001520510 T	07-09-1999 30-10-2001
			JP JP US	11510045 T 2001520510 T 6043344 A	07-09-1999 30-10-2001 28-03-2000
			JP JP US WO	11510045 T 2001520510 T 6043344 A 9704097 A2	07-09-1999 30-10-2001 28-03-2000 06-02-1997
			JP JP US	11510045 T 2001520510 T 6043344 A	07-09-1999 30-10-2001 28-03-2000





Information on patent family members

International lication No PCT/EP 03/50211

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0204015	A	17-01-2002	AU CA CA CN CN EP NO NO	1876902 A 7338701 A 2412150 A1 2412162 A1 1441808 T 1460023 T 1307216 A1 1299415 A1 20030110 A 20030111 A 0204015 A1	21-01-2002 21-01-2002 17-01-2002 17-01-2002 10-09-2003 03-12-2003 07-05-2003 09-04-2003 12-03-2003 12-03-2003 17-01-2002
			WO	0204499 A1	17-01-2002

Form PCT/ISA/210 (patent family annex) (July 1992)